Reinterpreting a ‘prime example’ of a born global: Cochlear's international launch

Abstract

Cochlear's first product, the 22-channel Nucleus implant, was the result of a research programme that has been dated back to 1967, when Graeme Clark, an ear, nose and throat (ENT) surgeon, commenced doctoral work on the electrical stimulation of the hearing nerve. Following the completion of his PhD in 1969, Clark was appointed the inaugural Chair in Otolaryngology at the University of Melbourne. When he joined the university in 1970, his primary objective was the practical application of his PhD research: namely, the development of a ‘bionic ear’, an electronic device that would stimulate the hearing nerve in the profoundly deaf. He realised early on that lack of resources would be one of his major impediments:across the road [from my office] the experimental research laboratory was in a disused hospital mortuary. When I looked at the mortuary my heart sank. It was dilapidated and bare. There was a stone table in the centre, but little else. The walls needed painting, and the light diffused poorly through the high windows. Anyway, I had no money to buy equipment even if the laboratory itself were satisfactory. (Clark, 2000, p. 54)

Citation

Hewerdine, L. and Welch, C. (2008), "Reinterpreting a ‘prime example’ of a born global: Cochlear's international launch", Feldman, M.P. and Santangelo, G.D. (Ed.) New Perspectives in International Business Research (Progress in International Business Research, Vol. 3), Emerald Group Publishing Limited, Leeds, pp. 189-206. https://doi.org/10.1016/S1745-8862(08)03009-4